Waterloopkunde: een eeuw wiskunde en werkelijkheid

Onderzoekers van het Waterloopkundig Lab, de Deltadienst van Rijkswaterstaat, TNO en het Mathematisch Centrum bestudeerden in vredige competitie het dynamisch gedrag van de Haringvlietsluizen. De uiteenlopende tradities om dewiskunde in dienst te stellen van de waterbouwkunde, schaalmodellen, analogons, wiskundige modellen en rekenwerk, kwamen in een zogenaamde klapclub samen. De beslissing bleef uit. Korte tijd later raakten al deze inspanningen op de achtergrond door de revolutie in de richting van een heel nieuw type rekenmodellen

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: The CHARISMA randomized multicenter clinical trial

Background: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate de

High Output LED in hybride belichting : monitoring praktijkproef bij Alstroemeria

In order to increase the intensity of the artificial light with the least possible electricity costs, an Alstroemeria production company experiments with a Hybrid light installation. The Hybrid lighting was created by complementing the existing 61 μmol/m2 HPS lamps with 21 μmol/m2s Philips High Output (HO) LED lamps to a total intensity of 81 μmol/m2s. The performance of this hybrid lighting was investigated between January 2017 and May 2019 and compared with the existing HPS installation (62 μmol/m2s) and with Regular Output (RO) LED at an intensity of 79 μmol/m2s. The light sum in the Hybrid lighting was 288 Mol/m2 higher than in the HPS reference (4%) thanks to the 33% higher light level and the 442 more burning hours of the HO LED, and yielded 8% more production (longer, heavier stems). The light sum in the LED treatment was 215 Mol light (3%) higher than the reference, due to 33% higher intensity but was used as many hours as the HPS lamps, and increased production by 6% (more branches). Of the three systems, the Full LED option is the most energy-efficient andthe Hybrid lighting had the lowest EUE (electricity use efficiency). The research was funded by the program “ Greenhouse as Source of Energy” of the Dutch Ministry of Agriculture and LTO Glaskracht, the Knowledge Cooperative Alstroemeria, Philips Lighting and Fa. Vreugdenhil

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

Background: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate definite overall survival benefit. This may partly be due to the fact that these studies often involve strict inclusion criteria. Consequently, patients with a high risk profile as characterized by Fong's Clinical Risk Score ( CRS) are often underrepresented in these studies. Conceptually, this group of patients might benefit the most from chemotherapy. The present study evaluates the impact of neo- adjuvant chemotherapy in high- risk patients with primary resectable colorectal liver metastases, without extrahepatic disease. Our hypothesis is that adding neo- adjuvant chemotherapy to surgery will provide an improvement in overall survival ( OS) in patients with a high- risk profile. Methods/ Design: CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to either surgery alone ( standard treatment, arm A) or to 6 cycles of neo- adjuvant oxaliplatin- based chemotherapy, followed by surgery ( arm B). Patients must be = 18 years of age with liver metastases of histologically confirmed primary colorectal carcinoma. Patients with extrahepatic metastases are excluded. Liver metastases must be deemed primarily resectable. Only patients with a CRS of 3- 5 are eligible. The primary study endpoint is OS. Secondary endpoints are progression free survival ( PFS), quality of life, morbidity of resection, treatment response on neo- adjuvant chemotherapy, and whether CEA levels can predict treatment response. Discussion: CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer to the question if adding neo- adjuvant chemotherapy to surgery will improve OS in a well- defined high- risk patient group with colorectal liver metastases

Linear and angular head accelerations during heading of a soccer ball

textabstractBackground: Efforts to improve the outcome of liver surgery by combining curative resection with chemotherapy have failed to demonstrate definite overall survival benefit. This may partly be due to the fact that these studies often involve strict inclusion criteria. Consequently, patients with a high risk profile as characterized by Fong's Clinical Risk Score (CRS) are often underrepresented in these studies. Conceptually, this group of patients might benefit the most from chemotherapy. The present study evaluates the impact of neo-adjuvant chemotherapy in high-risk patients with primary resectable colorectal liver metastases, without extrahepatic disease. Our hypothesis is that adding neo-adjuvant chemotherapy to surgery will provide an improvement in overall survival (OS) in patients with a high-risk profile. Methods/Design: CHARISMA is a multicenter, randomized, phase III clinical trial. Patients will be randomized to either surgery alone (standard treatment, arm A) or to 6 cycles of neo-adjuvant oxaliplatin-based chemotherapy, followed by surgery (arm B). Patients must be ≥ 18 years of age with liver metastases of histologically confirmed primary colorectal carcinoma. Patients with extrahepatic metastases are excluded. Liver metastases must be deemed primarily resectable. Only patients with a CRS of 3-5 are eligible. The primary study endpoint is OS. Secondary endpoints are progression free survival (PFS), quality of life, morbidity of resection, treatment response on neo-adjuvant chemotherapy, and whether CEA levels can predict treatment response. Discussion: CHARISMA is a multicenter, randomized, phase III clinical trial that will provide an answer to the question if adding neo-adjuvant chemotherapy to surgery will improve OS in a well-defined high-risk patient group with colorectal liver metastases. Trial registration: The CHARISMA is registered at European Union Clinical Trials Register (EudraCT), number: 2013-004952-39, and in the "Netherlands national Trial Register (NTR), number: 4893